Clinical Trial: Suprachoroidal Injection of CLS-TA in Subjects Non-infectious Uveitis

Study Status: Not yet recruiting
Recruit Status: Not yet recruiting
Study Type: Interventional

Official Title: Open-label Safety Study of Suprachoroidal Triamcinolone Acetonide Injectable Suspension in Patients With Non-Infectious Uveitis

Brief Summary: Open-label safety study of suprachoroidal triamcinolone acetone injectable suspension in patients with non-infectious uveitis.

Detailed Summary: This is a Phase 3, open-label, multi-center study to assess the safety of 4 mg of CLS-TA administered via suprachoroidal injection for the treatment of subjects with non-infectious uveitis.
Sponsor: Clearside Biomedical, Inc.

Current Primary Outcome: Adverse Events [ Time Frame: 24 weeks ]

Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), grouped by organ system, relatedness to study medication, and severity


Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Clearside Biomedical, Inc.

Dates:
Date Received: March 27, 2017
Date Started: April 1, 2017
Date Completion: June 2018
Last Updated: March 27, 2017
Last Verified: March 2017